Targeted Somatic Mutation (TSM)
GMDx Co. has developed a true platform technology that provides a wide suite of applications in monitoring the immune-like response of individuals, and for the personalisation of treatment plans. Our patent-pending proprietary Targeted Somatic Mutation (TSM) diagnostic test represents a novel advance in the area of clinical diagnostics.
The TSM platform implements proprietary algorithms to identify the source of de novo somatic mutations associated with the development of pre-cancerous conditions.
Background to Targeted Somatic Mutation (TSM) profile
GMDx Co. TSM profiling is able to identify the binding domain of specific deaminases actively causing mutations in an individual.
A clinical grade, cloud-based test platform is now available for clinical analysis. The system design is highly scalable, adaptable and robust. It is designed to meet the most demanding diagnostic, reporting and security requirements for future accreditation and certification.